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Summary. The article discusses the efficacy and 
tolerability of a non-steroidal anti-inflammatory domestic 
drug after cataract extraction, the severit y of side effects of 
a non-steroidal anti-inflammatory drug.
The aim of the study – optimization of methods of 
postoperative treatment of cataracts using the domestic 
non-steroidal anti-inflammatory Diclofenac drug, 0.1 % eye 
drops, produced by JV “Jurabek Laboratories” LLC.
Materials and Methods. The study included patients 
who were at inpatient treatment at the Clinic No. 2 of the 
Tashkent Medical Academy. The study group included 60 
people: 21 men and 39 women, the age of patients was 
18–73 years. In two groups, we compared the efficacy and 
tolerability of domestic and foreign NSAIDs after cataract 
extraction.
Results. The effectiveness of the complex treatment 
is confirmed by the reduction in the duration of relief of 
the main symptoms of inflammation in patients of both 
groups. Both drugs did not cause side effects and were 
well tolerated by patients. Tolerability of the treatment in the 
group receiving domestic NSAIDs was 93.4 %, in the group 
receiving foreign NSAIDs – 95.7 %.
Conclusions. According to the results of our studies, 
it was proved that therapy after cataract extraction with the 
use of a domestic-made NSAID is not inferior in efficiency 
and tolerability to a foreign-made drug and can be used in 
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Переносимості вітчизняного нестероїдного 
протизапального препарату в післяопераційному 
періоді екстракції катаракати
Ф. Бахрітдінова, К. І. Нарзікулова Кумру Ісламовна, 
Ш. А. Юсупов, М. Е. Егамбердіева
Ташкентська медична академія, Узбекистан 
Резюме. У статті розглянуто питання ефектив-
ності та переносимості вітчизняного нестероїдного 
протизапального засобу (НПЗЗ) після екстракції ката-
ракти, а також вираження його побічних ефектів.
Мета дослідження – оптимізувати  методи після-
операційного лікування катаракти з використанням 
вітчизняного нестероїдного протизапального препа-
рату «Диклофенак", 0,1% краплі очні виробництва СП 
ТОВ «Jurabek Laboratories».
Матеріали і методи. У дослідження були включені 
пацієнти, які перебували на стаціонарному лікуванні на 
базі 2 клініки Ташкентської медичної академії. До групи 
дослідження було включено 60 осіб: 21 чоловік і 39 жі-
нок, вік хворих становив 18–73 роки. У двох групах ми 
порівнювали ефективність і переносимість вітчизня-
ного і зарубіжного НПЗЗ після екстракції катаракти.
Результати. Ефективність комплексного ліку-
вання підтверджена скороченням термінів зникнення 
основних симптомів запалення у пацієнтів обох груп. 
Обидва препарати не викликали побічних дій і добре 
переносилися пацієнтами. Переносимість проведе-
ного лікування у групі, яка отримувала вітчизняний 
НПЗЗ, склала 93,4 %, а у групі, що отримувала НПЗП 
зарубіжного виробництва, – 95,7 %.
Висновки. За результатами проведених дослі-
джень доведено, що терапія після екстракції катарак-
ти із застосуванням препарату НПЗЗ вітчизняного 
виробництва не поступається за ефективністю і 
переносимістю препарату зарубіжного виробництва 
й може застосовуватися в післяопераційному періоді 
лікування катаракти.
Ключові слова: катаракта; нестероїдний протизапаль-
ний препарат; переносимість нестероїдного протиза-
пального препарату; побічні ефекти нестероїдного про-
тизапального препарату.
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INTRODUCTION
Cataracts, a clouding of the lens, is the leading 
cause of blindness in developing countries. Cataract 
surgery is recognized by the World Health Organization 
as the only fully rehabilitating operation among all 
surgical interventions.
The main goal of therapy after cataract extraction 
is to prevent complications, determine the cause of 
postoperative inflammation, maintain a normal level of 
patient activity and improve the quality of life [1, 2].
Cataract extraction is a surgical procedure to 
remove the lens of an eye that has become cloudy over 
time, impairing vision in that eye. This is part of a cataract 
surgery in which the removed lens is replaced with an 
artificial lens. The normal lens of the eye is clear and 
transparent, over time the lens becomes cloudy and 
vision becomes blurry as protein deposits accumulate 
on it, causing cataracts. Before cataract surgery, patients 
are usually given local anesthesia with eye drops or 
injection, and are often given additional medication to 
help the patient relax. An eye doctor (ophthalmologist) 
uses a special microscope to examine the eye. A shallow 
incision is made in the eye through which the lens is 
removed. Depending on the type of cataract, the 
surgeon may use sound waves to break the cataract 
into small pieces that will be sucked out of the eye 
through the incision; instrument for cataract removal in 
one piece with a large incision; or a laser to make 
incisions and soften the cataract before sucking it out. 
Using a laser instead of a scalpel can provide a more 
accurate cut and shorten recovery time. After removing 
the lens, the doctor replaces it with a clear lens called 
an intraocular lens and then closes the incision. The 
operation usually takes less than 30 minutes [3, 4, 9]. 
Using a laser instead of a scalpel can provide a more 
accurate cut and shorten recovery time. After removing 
the lens, the doctor replaces it with a clear lens called 
an intraocular lens and then closes the incision. The 
operation usually takes less than 30 minutes [3, 4, 9]. 
Using a laser instead of a scalpel can provide a more 
accurate cut and shorten recovery time. After removing 
the lens, the doctor replaces it with a clear lens called 
an intraocular lens and then closes the incision. The 
operation usually takes less than 30 minutes [3, 4, 9].
We evaluated the effectiveness of Diclofenac, 0.1 % 
5ml eye drops, produced by JV LLC "Jurabek 
Laboratories", after cataract extraction. Traditionally, 
drugs are selected based on controlled clinical trials.
Diclofenac is a proven, commonly prescribed non-
steroidal anti-inflammatory drug (NSAID) that has 
analgesic, anti-inflammatory and antipyretic properties 
and has been shown to be effective in the treatment of 
a variety of acute and chronic pain and inflammatory 
conditions. Like all NSAIDs, diclofenac exerts its action 
through inhibition of prostaglandin synthesis by inhibiting 
cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
(COX-2) with relative equipotency. However, extensive 
research shows that the pharmacological activity of 
Diclofenac goes beyond COX inhibition and includes 
multimodal and, in some cases, novel mechanisms of 
action. Diclofenac reduces eye inflammation, pain and 
discomfort in the eye (photophobia, burning, tingling, 
etc.) that can result from infection,
The aim of the study – optimization of methods 
of postoperative treatment of cataracts using the 
domestic non-steroidal anti-inflammatory drug 
Diclofenac, 0.1 % eye drops, produced by JV "Jurabek 
Laboratories" LLC.
MATERIALS AND METHODS
The study included patients who were at inpatient 
treatment at the Clinic No. 2 of the Tashkent Medical 
Academy. The study group included 60 people: 21 men 
and 39 women, the age of the patients was 18–73 
years.
Group 1 included 30 patients –18 women and 12 
men aged 19–57 (average age (34.6+0.1) years). 
Group 2 included 30 patients – 21 women and 9 men 
aged 19–43 (average age (32.5+0.1) years) (Table 1). 
Depending on the therapy, the patients were 
divided into 2 homogeneous groups: 30 patients each. 
Patients of the control group in the postoperative period 
were prescribed NSAID of foreign production Diclofenac 
ophthalmic 0.1 % eye drops, 5 ml, manufactured by 
CJSC "Liquor", Armenia, 2 drops 4 times a day. In the 
main group of patients, NSAID of domestic production 
Diclofenac 0.1 % 5 ml was prescribed – eye drops, 
produced by JV "Jurabek Laboratories" LLC, 
Uzbekistan, 2 drops 4 times a day. All patients, in 
addition to the above drugs, were prescribed antibiotic 
therapy. The treatment was carried out for 10 days.
Table 1. Characteristics of research groups
Distribution of patients Study drug Comparison drug




By age Average age Average age
Men 37.0 30.6
Women 33.1 33.2
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The severity of side effects is assessed on a 4-point 
scale:
0 points – no side effects (well tolerated); 
1 point – light side effects (well tolerated);
2 points – moderate side effects (tolerated 
satisfactorily);
3 points – side effects are pronounced (poorly 
tolerated).
4 points – severe side effects (very poorly tolerated)
RESULTS AND DISCUSSION
In the postoperative period, the objective symptoms 
were: injection of the vessels of the conjunctiva and 
sclera, conjunctival edema and unexpressed 
lacrimation. 
The tolerability of the drug was assessed according 
to the following subjective data: burning sensation and 
tingling sensation when instilled, short-term blurred 
vision. In the main group, in which the patients were 
instilled with Diclofenac, 0.1 % 5 ml eye drops, 
produced by JV LLC "Jurabek Laboratories", 
Uzbekistan, burning sensation during instillation was 
observed in varying degrees in all patients (100 %), 
short-term blurred vision in 20 % of patients. In the 
comparison group, in which the patients were instilled 
with Diclofenac Ophthalmic 0.1 % eye drops, 5 ml, 
produced by CJSC “Likvor”, Armenia, a burning 
sensation was also observed in varying degrees in all 
patients (100 %), short-term blurred vision was 
observed in 6 % of patients.
Tolerability of the ongoing treatment in the group 
receiving Diclofenac, 0.1 % 5 ml (eye drops, produced 
by JV LLC "Jurabek Laboratories", Uzbekistan) was 
assessed as high 93.4 %. and 96.7 %, respectively 
(Table 2). 
The effectiveness of the complex treatment is 
confirmed by the shortening of the time for relief of 
the main symptoms of inflammation in patients of 
both groups. Subjective improvement in the condition 
of the eyes in patients of the main and control groups 
was noted already on the next day from the start of 
treatment. On day 3 of treatment, there was a 
positive trend in all objective parameters: the 
cessation of lacrimation was noted, there was no 
edema, injection of the vessels of the conjunctiva 
and sclera: in 100 % in the control group and 96.7 
% in the main group.
Both drugs did not cause side effects and were well 
tolerated by patients. Only 20 % of patients in the main 
group and 16 % of patients in the control group had a 
short-term burning sensation, which subsided within 1 
minute. Tolerability of the treatment in the group 
receiving domestic NSAIDs was 93.4 %, in the group 
receiving foreign NSAIDs – 95.7 %.
Table 2. Evaluation of efficacy and tolerability in patients of both groups in % ratio (n-number of patients)
Estimated indicators Main group Comparison group
Score 0 1 2 3 4 0 1 2 3 4










According to the results of our studies, it was 
proved that therapy after cataract extraction with the 
use of a domestic-made NSAID is not inferior in 
efficiency and tolerability to a foreign-made drug and 
can be used in the postoperative period of cataract.
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